A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...

Полное описание

Библиографические подробности
Главные авторы:	Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD
Формат:	Статья
Язык:	English
Опубликовано:	SAGE Publishing 2022-09-01
Серии:	Cancer Control
Online-ссылка:	https://doi.org/10.1177/10732748221130576

Схожие документы

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
по: Hiroki Hata MS, и др.
Опубликовано: (2020-12-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
по: Hideo Oishi, MD, и др.
Опубликовано: (2020-10-01)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
по: Arthur E. Frankel MD, и др.
Опубликовано: (2019-04-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
по: Taichi Miyawaki, MD, и др.
Опубликовано: (2020-06-01)

Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
по: Bilguun Erkhem-Ochir, MD, и др.
Опубликовано: (2021-03-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
по: Samit Chatterjee PhD, и др.
Опубликовано: (2017-07-01)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
по: Tara Davidson, MD, и др.
Опубликовано: (2022-07-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
по: Chenxing Zhang, PhD, и др.
Опубликовано: (2020-03-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
по: Daisuke Hazama, MD, PhD, и др.
Опубликовано: (2024-01-01)

A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisNovel Teaching Points
по: Tatsuya Nishikawa, MD, PhD, и др.
Опубликовано: (2022-07-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
по: Kenji Morimoto, MD, PhD, и др.
Опубликовано: (2022-09-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
по: Mariana Mirabel, MD, PhD, и др.
Опубликовано: (2020-09-01)

A Modified Method for the Quantification of Immune Checkpoint Ligands on Exosomes from Human Serum using Flow Cytometry
по: Alan Guillermo Alejandre Gonzalez PhD, и др.
Опубликовано: (2023-05-01)

A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8
по: Amanda Leiter, MD, MSCR, и др.
Опубликовано: (2020-07-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
по: Yasunori Murata, MD, PhD, и др.
Опубликовано: (2023-12-01)

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
по: Fatih Kus MD, и др.
Опубликовано: (2024-09-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
по: Shiting Xu, MD, и др.
Опубликовано: (2022-04-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
по: Yuto Terashima, MD, и др.
Опубликовано: (2023-11-01)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
по: Xinlun Dai MD, и др.
Опубликовано: (2020-08-01)

Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis
по: Lianghui Zhang MS, и др.
Опубликовано: (2024-08-01)

A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis
по: Mahdieh Azizi, PhD, и др.
Опубликовано: (2024-01-01)

Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma
по: Qiang Liu PhD, и др.
Опубликовано: (2024-04-01)

Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes
по: Etienne Charpentier, MD, и др.
Опубликовано: (2024-01-01)

Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors
по: Jack M. Qian, MD, и др.
Опубликовано: (2022-03-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
по: Mandy Jongbloed, MD, и др.
Опубликовано: (2025-03-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
по: Dorothy M. Gujral, PhD, и др.
Опубликовано: (2020-02-01)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
по: Ying Teng PhD, и др.
Опубликовано: (2022-03-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
по: Tristan V.M. Bruijn, MD, и др.
Опубликовано: (2024-05-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
по: Kana Hashimoto, MD, и др.
Опубликовано: (2024-11-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
по: Natalie Bourand, MS, и др.
Опубликовано: (2025-02-01)

Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo
по: Hsin-Ling Yang PhD, и др.
Опубликовано: (2017-09-01)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
по: Roger Y. Kim, MD, и др.
Опубликовано: (2021-06-01)

Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
по: Benjamin M.P. Elyan, MBChB, и др.
Опубликовано: (2023-07-01)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
по: Marco Tagliamento, MD, и др.
Опубликовано: (2023-01-01)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
по: Denis L. Jardim MD, PhD, и др.
Опубликовано: (2018-12-01)

Seeking “protective” and “harmful” immune genes during chronic HIV-1 infection by transcriptome analysis
по: Lingyan Zhu, PhD, и др.
Опубликовано: (2018-09-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
по: Alicia Quilez, MD, и др.
Опубликовано: (2020-03-01)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation
по: Jia-Jun Wu, MD, и др.
Опубликовано: (2022-06-01)

The Value of Combined Detection of Megakaryocyte and Platelet Parameters for the Diagnosis of Primary Immune Thrombocytopenia
по: Weiwei Wang MS, и др.
Опубликовано: (2022-08-01)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
по: Sakeena Fatima, BA, и др.
Опубликовано: (2018-04-01)